View ValuationJiangsu Hengrui PharmaceuticalsLtd 향후 성장Future 기준 점검 2/6Jiangsu Hengrui PharmaceuticalsLtd (는) 각각 연간 15.9% 및 13.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15% 로 예상됩니다.핵심 정보15.9%이익 성장률16.04%EPS 성장률Pharmaceuticals 이익 성장15.1%매출 성장률13.1%향후 자기자본이익률14.95%애널리스트 커버리지Good마지막 업데이트31 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 23Jiangsu Hengrui Pharmaceuticals Co., Ltd. Receive Nmpa Approval for Camrelizumab and Famitinib Combination as First-Line Treatment for Recurrent or Metastatic Cervical CancerJiangsu Hengrui Pharmaceuticals Co. Ltd. and its subsidiary, Suzhou Suncadia Biopharmaceuticals Co. Ltd., received notification from the National Medical Products Administration approving the market launch of the Company's innovative drug, camrelizumab for injection in combination with famitinib malate capsules, as a first-line treatment for patients with recurrent or metastatic cervical cancer. With this approval, the targeted immunotherapy combination regimen has now been formally upgraded from second-line ("2L") to first-line ("1L") therapy for advanced cervical cancer. Camrelizumab for injection in combination with famitinib malate is indicated for the first-line treatment of patients with recurrent or metastatic cervical cancer who have PD-L1-positive expression (combined positive score (CPS) = 1), as assessed by a fully validated test method. Camrelizumab for injection has been approved in China for multiple indications, including advanced hepatocellular carcinoma, non-squamous non-small cell lung cancer, esophageal squamous cell carcinoma, advanced nasopharyngeal carcinoma, and others. Famitinib malate capsules were approved in May 2025 for use in combination with camrelizumab for injection in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and have not received bevacizumab treatment, and this indication was converted from conditional approval to full approval in July 2026. This approval is based on a randomized, open-label, controlled, multi-center phase III clinical study of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer (SHR-1210-III-329). A total of 45 study sites in China participated in the study, enrolling 443 patients. All prespecified primary endpoints were met. As of June 10, 2025, the median follow-up in the PD-L1-positive subgroup was 19.5 months, demonstrating that camrelizumab in combination with famitinib malate significantly improved survival benefit in patients with advanced cervical cancer. In the PD-L1-positive population, the median overall survival (OS) was 35.8 months in the combination group versus 23.6 months in the chemotherapy group, corresponding to a significant 36.6% reduction in the risk of death (HR = 0.634).공고 • Jun 30+ 1 more updateHengrui Pharma Receives Approval For Heng Yi Cyclosporine Ophthalmic Solution For Dry Eye Disease In ChinaHengrui Pharma and Novaliq GmbH announced that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. Heng Yi is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol platform technology, following the approval of Heng Qin (perfluorohexyloctane ophthalmic solution) in 2025. Heng Yi combines the proven anti-inflammatory drug cyclosporine with the vehicle perfluorobutylpentane, a semifluorinated alkane (SFA) designed to overcome the drug’s usual limitations. The spreading properties of the water-free vehicle reduce friction and thereby contribute to the efficacy. The approval in China is based on a randomized, double-blind, vehicle-controlled Phase III clinical trial (Study SHR8028-301) led by the team of Professor Hong Jing at Peking University Third Hospital. Results showed that Heng Yi significantly improved total corneal fluorescein staining (tCFS) score as early as Day 15 (treatment group: -4.0 vs control group: -2.8, P=0.008). At Day 29, treatment with Heng Yi significantly reduced tCFS score (treatment group: -4.8 vs control group: -3.0, P<0.0001). The product demonstrated a favorable safety and tolerability profile. This novel cyclosporine ophthalmic solution (development name CyclASol) was approved by the U.S. Food and Drug Administration (FDA) and launched in the United States in 2023 as the world's first cyclosporine ophthalmic solution indicated for the treatment of signs and symptoms of dry eye disease. In Europe, the product was reviewed by the European Medicines Agency (EMA) and centrally approved in the European Union in September 2024 for the treatment of adults with moderate to severe dry eye disease. The SHR8028-301 clinical trial is a multicenter, randomized, double-blind, vehicle-controlled Phase III trial (NCT05841043) conducted by Hengrui Pharma in China, designed to evaluate the efficacy and safety of 0.1% cyclosporine ophthalmic solution (development code: SHR8028) in adult patients with moderate-to-severe DED. A total of 206 subjects were enrolled and randomized in a 1:1 ratio to receive either SHR8028 or vehicle twice daily. The primary endpoints were improvements in tCFS score and eye dryness VAS score in dry eye patients at Day 29 with SHR8028 compared with vehicle. SHR8028-301 is a bridging study in China of the ESSENCE-2 clinical trial. The ESSENCE-2 (NCT04043179) clinical trial is a multicenter, randomized, double-blind, vehicle-controlled Phase III trial sponsored by Novaliq, conducted in the US across multiple regions, designed to evaluate the efficacy and safety of 0.1% cyclosporine ophthalmic solution (development name: CyclASol, SHR8028 in China) in adult patients with moderate-to-severe DED. ESSENCE-2 enrolled 834 subjects, who were randomized in a 1:1 ratio to receive either 0.1% cyclosporine ophthalmic solution or vehicle twice daily. The primary endpoints were improvements in tCFS score and eye dryness VAS score in dry eye patients at Day 29 (Week 4) with CyclASol compared to vehicle. ESSENCE-2 met its primary sign endpoint. The effect on tCFS score was observed as early as Day 15 (treatment group: -3.5 vs control group: -3.0, P=0.002). Importantly, 71.6% of patients responded within four weeks with a clinically meaningful improvement of =3 grades in total corneal staining. The ESSENCE-2 OLE clinical trial is a multicenter, open-label, single-arm trial (NCT04180109) initiated by Novaliq, designed to evaluate the long-term efficacy, safety, and tolerability of CyclASol in adult patients with DED. The study enrolled 202 subjects who had completed treatment in the ESSENCE-2 clinical trial. All subjects received CyclASol twice daily for 12 months. The primary endpoints were to assess the safety of CyclASol during long-term administration and to observe the long-term improvements in corneal and conjunctival staining scores and dry eye symptom scores in patients with DED. In the study, over 80% of patients achieved a significant improvement of =3 points in tCFS score after 4 weeks in the study which was maintained over the 12 months study period, making it well-suited for long-term management of DED as a chronic disease. Together with Heng Qin (perfluorohexyloctane ophthalmic solution), having an anti-evaporative mode-of-action, Hengrui Pharma is uniquely positioned to offer an innovative and comprehensive treatment portfolio for patients across the most common disease root causes of dry eye disease in China.공고 • Jun 10Hengrui Pharma Presents More Than 90 Oncology Studies At ASCO 2026 Highlighting Progress Across Multiple Tumor TypesHengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities. At 2026 ASCO Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). For triple-negative breast cancer, the HELEN-Trio 011 study showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity. In the field of colorectal cancer, the HORIZON-CRC01 study demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with standard-of-care (SOC), suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of hepatocellular carcinoma, the phase III CARES-336 trial demonstrated that the combination of camrelizumab plus rivoceranib with transarterial chemoembolization (TACE) significantly improved median progression-free survival (PFS) versus TACE alone (11.1 vs. 8.3 months; BICR-assessed per mRECIST). This triplet regimen represents a new benchmark for systemic-combined locoregional therapy for patients with unresectable HCC (uHCC). The FUZUPRO study demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction. The Phase III PROTECT study demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs. Hengrui's expanding presence at the ASCO Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company's research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio.공고 • Apr 17+ 1 more updateJiangsu Hengrui Pharmaceuticals Co.,Ltd Announces Board and Committee ChangesJiangsu Hengrui Pharmaceuticals Co.,Ltd at the AGM held on April 16, 2026, approved election of Mr. Lou Liguang as an independent non-executive Director, of the tenth session of the Board. The tenth session of the Board became effective on the date of the Shareholders' Meeting and the term of office of each the member of the tenth session of the Board shall be three years. Upon the election of the tenth session of the Board, Mr. Dong Jiahong, an independent non-executive Director of the ninth session of the Board, will retire from the positions of an independent non-executive Director, the chairperson of the Nomination Committee, a member of the Audit Committee and a member of the Strategy Committee, all effective from the date of the conclusion of the Shareholders' Meeting. Upon the retirement taking effect, Mr. Dong no longer holds any position in the Company. Mr. Dong has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited. In the Board Meeting, the Board has resolved to elect Ms. Feng Ji as chief operating officer of the Company; and Mr. Zhu Guoxin as the senior vice presidents of the Company. Upon the election and approval by the Directors in the Board Meeting, the composition of the Board committees under the tenth session of the Board is as follows: Audit Committee: Mr. Zeng Qingsheng (Chairperson), Mr. Sun Jinyun, Mr. Lou Liguang, Mr. Chow Kyan Mervyn. Remuneration and Evaluation Committee: Mr. Sun Jinyun (Chairperson), Mr. Dai Hongbin, Mr. Zeng Qingsheng. Nomination Committee: Mr. Sun Jinyun (Chairperson), Ms. Feng Ji, Mr. Zeng Qingsheng. Strategy Committee: Mr. Sun Piaoyang (Chairperson), Mr. Dai Hongbin, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun, Ms. Guo Congzhao, Mr. Lou Liguang.공고 • Mar 30+ 1 more updateHengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With HRS/BHB-1893 In Obstructive Hypertrophic CardiomyopathyHengrui Pharma, and Braveheart Bio announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). In the 42 patient study, HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G), an established measure of cardiac obstruction. The multi-center, randomized, open-label Phase 2 dose-ranging study (NCT06516068 [1]) of 42 patients was designed to measure efficacy and safety of BHB/HRS-1893 and to evaluate dose regimen options that could shorten the time to an effective dose. Patients were randomized 1:1:1 to receive oral BHB/HRS-1893 20 mg twice daily (potentially titrated up to 60 mg; Group 1), 40 mg twice daily (potentially titrated up to 80 mg; Group 2) or 40 mg once-daily (potentially titrated up to 120 mg; Group 3), for 12 weeks. The study design included the option for individual dosage adjustment based on evaluation of left ventricular ejection fraction (LVEF) and Valsalva LVOT-G. The primary endpoint was change in Valsalva LVOT-G from baseline to Week 12. BHB/HRS-1893 treatment resulted in rapid and substantial reductions in LVOT-G with minimal change in LVEF across dose groups. Range of complete Valsalva LVOT-G response (<30 mmHg) was between 50% and 86% and the range of LVEF decrease was between 1.8% and 2.7%. BHB/HRS-1893 displayed rapid onset of effect, with the average Valsalva LVOT-G below 30 mmHg as early as day 5. The study found 89% of patients well served at a 40 mg or 60 mg twice-daily dose regimen, with minimal to no titration required to achieve the target dose. All patients were titrated to a final dose based solely on gradient reduction below LVOT-G <30 mmHg. BHB/HRS-1893 treatment also demonstrated improvements in key secondary and exploratory measures in Group 2, the dose selected for open-label extension (OLE), including increase in pVO2 of 1.0 mL/kg/min, KCCQ-CSS of 10.5 points, and reduction in NT-proBNP of 88%. All 42 patients enrolled in the OLE part of the study and continued to receive administration of BHB/HRS-1893. At Week 39 of the OLE, the complete Valsalva LVOT-G response rate was 88%. BHB/HRS-1893 was generally well tolerated, and no new safety signals were identified in the 12-week study period. Reported adverse events were mild to moderate in severity, and no adverse events led to treatment interruption or discontinuation. No patients experienced ejection fraction values below 55% during the 12-week study period. Results of the study were highlighted in a late-breaking featured clinical research presentation at the American College of Cardiology's Annual Scientific Session & Expo. HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 aims to address the underlying pathophysiology of HCM while maintaining cardiac output. HRS-1893 has undergone extensive clinical development, including a dose-ranging Phase 2 study in symptomatic oHCM, an ongoing Phase 2 study in nHCM, multiple clinical pharmacology studies including a bridging study in Australia and an ongoing Phase 3 study in oHCM in China (NCT07021976 [2]). Braveheart Bio entered into an exclusive worldwide license agreement with Hengrui Pharma for the development, manufacture and commercialization of HRS-1893, outside of Mainland China, the Hong Kong SAR, the Macao SAR and Taiwan Region.공고 • Mar 26Jiangsu Hengrui Pharmaceuticals Co.,Ltd Proposes A Cash Dividend for the Year 2025Jiangsu Hengrui Pharmaceuticals Co.,Ltd proposed to distribute a cash dividend of RMB 2 (tax inclusive) per 10 Shares to all Shareholders for the year 2025. As of March 16, 2026, the Company's total share capital amounted to 6,637,199,874 Shares, of which 6,787,650 Shares were held in the stock repurchase account. Pursuant to applicable regulations, such Shares held in the stock repurchase account are not entitled to participate in the profit distribution for the current period. Based on the foregoing, the total cash dividend proposed for distribution is RMB 1,326,082,444.80 (tax inclusive). The actual amount of cash dividend to be distributed will be adjusted according to the number of Shares held in the Company's stock repurchase account as of the record date for dividend distribution.공고 • Mar 25Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Annual General Meeting, Apr 16, 2026Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Annual General Meeting, Apr 16, 2026, at 14:30 China Standard Time. Location: No. 1288, Haike Road, Pudong New Area, Shanghai China이익 및 매출 성장 예측OTCPK:JHPC.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202847,76813,16611,47612,9851512/31/202741,04710,8719,35911,5511712/31/202635,5619,1447,5238,885173/31/202632,5648,1198,50211,467N/A12/31/202531,6297,7118,27311,235N/A9/30/202530,9837,4689,78911,948N/A6/30/202530,1457,3556,4188,690N/A3/31/202529,1936,8424,6136,723N/A12/31/202427,9856,3375,4547,423N/A9/30/202425,9955,4486,2827,920N/A6/30/202425,2525,4266,3387,801N/A3/31/202423,3254,4327,0248,684N/A12/31/202322,8204,3026,1607,644N/A9/30/202322,3444,2071,5593,387N/A6/30/202322,2164,0951,7973,295N/A3/31/202321,2893,909-3461,331N/A12/31/202221,2753,906-7271,265N/A9/30/202221,6523,4961,0382,908N/A6/30/202222,8363,9821,1443,566N/A3/31/202224,4554,2712,1024,168N/A12/31/202125,9064,5302,5544,219N/A9/30/202128,5206,2771,4232,944N/A6/30/202129,7236,3344121,554N/A3/31/202129,1376,5101,2902,088N/A12/31/202027,7356,3282,8783,432N/A9/30/202025,7575,8524,5745,195N/A6/30/202024,5715,5775,1775,741N/A3/31/202023,8495,4514,3884,933N/A12/31/201923,2895,328N/A3,817N/A9/30/201921,9044,889N/A3,332N/A6/30/201919,6834,568N/A2,899N/A3/31/201918,5284,309N/A2,706N/A12/31/201817,4184,066N/A2,774N/A9/30/201816,2283,801N/A2,336N/A6/30/201815,2523,553N/A2,518N/A3/31/201814,5233,354N/A2,433N/A12/31/201713,8363,217N/A2,547N/A9/30/201712,8962,988N/A2,928N/A6/30/201712,1592,848N/A2,666N/A3/31/201711,5942,716N/A2,630N/A12/31/201611,0942,589N/A2,593N/A9/30/201610,7092,529N/A2,653N/A6/30/201610,2092,425N/A2,517N/A3/31/20169,7812,309N/A2,444N/A12/31/20159,3162,172N/A2,277N/A9/30/20158,8331,970N/A2,021N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: JHPC.Y 의 연간 예상 수익 증가율(15.9%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: JHPC.Y 의 연간 수익(15.9%)이 US 시장(16.4%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: JHPC.Y 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: JHPC.Y 의 수익(연간 13.1%)이 US 시장(연간 12.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: JHPC.Y 의 수익(연간 13.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: JHPC.Y의 자본 수익률은 3년 후 15%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 09:41종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Jiangsu Hengrui Pharmaceuticals Co.,Ltd는 37명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rebecca LiangBernsteinBo LiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.34명의 분석가 더 보기
공고 • Jul 23Jiangsu Hengrui Pharmaceuticals Co., Ltd. Receive Nmpa Approval for Camrelizumab and Famitinib Combination as First-Line Treatment for Recurrent or Metastatic Cervical CancerJiangsu Hengrui Pharmaceuticals Co. Ltd. and its subsidiary, Suzhou Suncadia Biopharmaceuticals Co. Ltd., received notification from the National Medical Products Administration approving the market launch of the Company's innovative drug, camrelizumab for injection in combination with famitinib malate capsules, as a first-line treatment for patients with recurrent or metastatic cervical cancer. With this approval, the targeted immunotherapy combination regimen has now been formally upgraded from second-line ("2L") to first-line ("1L") therapy for advanced cervical cancer. Camrelizumab for injection in combination with famitinib malate is indicated for the first-line treatment of patients with recurrent or metastatic cervical cancer who have PD-L1-positive expression (combined positive score (CPS) = 1), as assessed by a fully validated test method. Camrelizumab for injection has been approved in China for multiple indications, including advanced hepatocellular carcinoma, non-squamous non-small cell lung cancer, esophageal squamous cell carcinoma, advanced nasopharyngeal carcinoma, and others. Famitinib malate capsules were approved in May 2025 for use in combination with camrelizumab for injection in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and have not received bevacizumab treatment, and this indication was converted from conditional approval to full approval in July 2026. This approval is based on a randomized, open-label, controlled, multi-center phase III clinical study of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer (SHR-1210-III-329). A total of 45 study sites in China participated in the study, enrolling 443 patients. All prespecified primary endpoints were met. As of June 10, 2025, the median follow-up in the PD-L1-positive subgroup was 19.5 months, demonstrating that camrelizumab in combination with famitinib malate significantly improved survival benefit in patients with advanced cervical cancer. In the PD-L1-positive population, the median overall survival (OS) was 35.8 months in the combination group versus 23.6 months in the chemotherapy group, corresponding to a significant 36.6% reduction in the risk of death (HR = 0.634).
공고 • Jun 30+ 1 more updateHengrui Pharma Receives Approval For Heng Yi Cyclosporine Ophthalmic Solution For Dry Eye Disease In ChinaHengrui Pharma and Novaliq GmbH announced that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. Heng Yi is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol platform technology, following the approval of Heng Qin (perfluorohexyloctane ophthalmic solution) in 2025. Heng Yi combines the proven anti-inflammatory drug cyclosporine with the vehicle perfluorobutylpentane, a semifluorinated alkane (SFA) designed to overcome the drug’s usual limitations. The spreading properties of the water-free vehicle reduce friction and thereby contribute to the efficacy. The approval in China is based on a randomized, double-blind, vehicle-controlled Phase III clinical trial (Study SHR8028-301) led by the team of Professor Hong Jing at Peking University Third Hospital. Results showed that Heng Yi significantly improved total corneal fluorescein staining (tCFS) score as early as Day 15 (treatment group: -4.0 vs control group: -2.8, P=0.008). At Day 29, treatment with Heng Yi significantly reduced tCFS score (treatment group: -4.8 vs control group: -3.0, P<0.0001). The product demonstrated a favorable safety and tolerability profile. This novel cyclosporine ophthalmic solution (development name CyclASol) was approved by the U.S. Food and Drug Administration (FDA) and launched in the United States in 2023 as the world's first cyclosporine ophthalmic solution indicated for the treatment of signs and symptoms of dry eye disease. In Europe, the product was reviewed by the European Medicines Agency (EMA) and centrally approved in the European Union in September 2024 for the treatment of adults with moderate to severe dry eye disease. The SHR8028-301 clinical trial is a multicenter, randomized, double-blind, vehicle-controlled Phase III trial (NCT05841043) conducted by Hengrui Pharma in China, designed to evaluate the efficacy and safety of 0.1% cyclosporine ophthalmic solution (development code: SHR8028) in adult patients with moderate-to-severe DED. A total of 206 subjects were enrolled and randomized in a 1:1 ratio to receive either SHR8028 or vehicle twice daily. The primary endpoints were improvements in tCFS score and eye dryness VAS score in dry eye patients at Day 29 with SHR8028 compared with vehicle. SHR8028-301 is a bridging study in China of the ESSENCE-2 clinical trial. The ESSENCE-2 (NCT04043179) clinical trial is a multicenter, randomized, double-blind, vehicle-controlled Phase III trial sponsored by Novaliq, conducted in the US across multiple regions, designed to evaluate the efficacy and safety of 0.1% cyclosporine ophthalmic solution (development name: CyclASol, SHR8028 in China) in adult patients with moderate-to-severe DED. ESSENCE-2 enrolled 834 subjects, who were randomized in a 1:1 ratio to receive either 0.1% cyclosporine ophthalmic solution or vehicle twice daily. The primary endpoints were improvements in tCFS score and eye dryness VAS score in dry eye patients at Day 29 (Week 4) with CyclASol compared to vehicle. ESSENCE-2 met its primary sign endpoint. The effect on tCFS score was observed as early as Day 15 (treatment group: -3.5 vs control group: -3.0, P=0.002). Importantly, 71.6% of patients responded within four weeks with a clinically meaningful improvement of =3 grades in total corneal staining. The ESSENCE-2 OLE clinical trial is a multicenter, open-label, single-arm trial (NCT04180109) initiated by Novaliq, designed to evaluate the long-term efficacy, safety, and tolerability of CyclASol in adult patients with DED. The study enrolled 202 subjects who had completed treatment in the ESSENCE-2 clinical trial. All subjects received CyclASol twice daily for 12 months. The primary endpoints were to assess the safety of CyclASol during long-term administration and to observe the long-term improvements in corneal and conjunctival staining scores and dry eye symptom scores in patients with DED. In the study, over 80% of patients achieved a significant improvement of =3 points in tCFS score after 4 weeks in the study which was maintained over the 12 months study period, making it well-suited for long-term management of DED as a chronic disease. Together with Heng Qin (perfluorohexyloctane ophthalmic solution), having an anti-evaporative mode-of-action, Hengrui Pharma is uniquely positioned to offer an innovative and comprehensive treatment portfolio for patients across the most common disease root causes of dry eye disease in China.
공고 • Jun 10Hengrui Pharma Presents More Than 90 Oncology Studies At ASCO 2026 Highlighting Progress Across Multiple Tumor TypesHengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities. At 2026 ASCO Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). For triple-negative breast cancer, the HELEN-Trio 011 study showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity. In the field of colorectal cancer, the HORIZON-CRC01 study demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with standard-of-care (SOC), suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of hepatocellular carcinoma, the phase III CARES-336 trial demonstrated that the combination of camrelizumab plus rivoceranib with transarterial chemoembolization (TACE) significantly improved median progression-free survival (PFS) versus TACE alone (11.1 vs. 8.3 months; BICR-assessed per mRECIST). This triplet regimen represents a new benchmark for systemic-combined locoregional therapy for patients with unresectable HCC (uHCC). The FUZUPRO study demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction. The Phase III PROTECT study demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs. Hengrui's expanding presence at the ASCO Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company's research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio.
공고 • Apr 17+ 1 more updateJiangsu Hengrui Pharmaceuticals Co.,Ltd Announces Board and Committee ChangesJiangsu Hengrui Pharmaceuticals Co.,Ltd at the AGM held on April 16, 2026, approved election of Mr. Lou Liguang as an independent non-executive Director, of the tenth session of the Board. The tenth session of the Board became effective on the date of the Shareholders' Meeting and the term of office of each the member of the tenth session of the Board shall be three years. Upon the election of the tenth session of the Board, Mr. Dong Jiahong, an independent non-executive Director of the ninth session of the Board, will retire from the positions of an independent non-executive Director, the chairperson of the Nomination Committee, a member of the Audit Committee and a member of the Strategy Committee, all effective from the date of the conclusion of the Shareholders' Meeting. Upon the retirement taking effect, Mr. Dong no longer holds any position in the Company. Mr. Dong has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited. In the Board Meeting, the Board has resolved to elect Ms. Feng Ji as chief operating officer of the Company; and Mr. Zhu Guoxin as the senior vice presidents of the Company. Upon the election and approval by the Directors in the Board Meeting, the composition of the Board committees under the tenth session of the Board is as follows: Audit Committee: Mr. Zeng Qingsheng (Chairperson), Mr. Sun Jinyun, Mr. Lou Liguang, Mr. Chow Kyan Mervyn. Remuneration and Evaluation Committee: Mr. Sun Jinyun (Chairperson), Mr. Dai Hongbin, Mr. Zeng Qingsheng. Nomination Committee: Mr. Sun Jinyun (Chairperson), Ms. Feng Ji, Mr. Zeng Qingsheng. Strategy Committee: Mr. Sun Piaoyang (Chairperson), Mr. Dai Hongbin, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun, Ms. Guo Congzhao, Mr. Lou Liguang.
공고 • Mar 30+ 1 more updateHengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With HRS/BHB-1893 In Obstructive Hypertrophic CardiomyopathyHengrui Pharma, and Braveheart Bio announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). In the 42 patient study, HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G), an established measure of cardiac obstruction. The multi-center, randomized, open-label Phase 2 dose-ranging study (NCT06516068 [1]) of 42 patients was designed to measure efficacy and safety of BHB/HRS-1893 and to evaluate dose regimen options that could shorten the time to an effective dose. Patients were randomized 1:1:1 to receive oral BHB/HRS-1893 20 mg twice daily (potentially titrated up to 60 mg; Group 1), 40 mg twice daily (potentially titrated up to 80 mg; Group 2) or 40 mg once-daily (potentially titrated up to 120 mg; Group 3), for 12 weeks. The study design included the option for individual dosage adjustment based on evaluation of left ventricular ejection fraction (LVEF) and Valsalva LVOT-G. The primary endpoint was change in Valsalva LVOT-G from baseline to Week 12. BHB/HRS-1893 treatment resulted in rapid and substantial reductions in LVOT-G with minimal change in LVEF across dose groups. Range of complete Valsalva LVOT-G response (<30 mmHg) was between 50% and 86% and the range of LVEF decrease was between 1.8% and 2.7%. BHB/HRS-1893 displayed rapid onset of effect, with the average Valsalva LVOT-G below 30 mmHg as early as day 5. The study found 89% of patients well served at a 40 mg or 60 mg twice-daily dose regimen, with minimal to no titration required to achieve the target dose. All patients were titrated to a final dose based solely on gradient reduction below LVOT-G <30 mmHg. BHB/HRS-1893 treatment also demonstrated improvements in key secondary and exploratory measures in Group 2, the dose selected for open-label extension (OLE), including increase in pVO2 of 1.0 mL/kg/min, KCCQ-CSS of 10.5 points, and reduction in NT-proBNP of 88%. All 42 patients enrolled in the OLE part of the study and continued to receive administration of BHB/HRS-1893. At Week 39 of the OLE, the complete Valsalva LVOT-G response rate was 88%. BHB/HRS-1893 was generally well tolerated, and no new safety signals were identified in the 12-week study period. Reported adverse events were mild to moderate in severity, and no adverse events led to treatment interruption or discontinuation. No patients experienced ejection fraction values below 55% during the 12-week study period. Results of the study were highlighted in a late-breaking featured clinical research presentation at the American College of Cardiology's Annual Scientific Session & Expo. HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 aims to address the underlying pathophysiology of HCM while maintaining cardiac output. HRS-1893 has undergone extensive clinical development, including a dose-ranging Phase 2 study in symptomatic oHCM, an ongoing Phase 2 study in nHCM, multiple clinical pharmacology studies including a bridging study in Australia and an ongoing Phase 3 study in oHCM in China (NCT07021976 [2]). Braveheart Bio entered into an exclusive worldwide license agreement with Hengrui Pharma for the development, manufacture and commercialization of HRS-1893, outside of Mainland China, the Hong Kong SAR, the Macao SAR and Taiwan Region.
공고 • Mar 26Jiangsu Hengrui Pharmaceuticals Co.,Ltd Proposes A Cash Dividend for the Year 2025Jiangsu Hengrui Pharmaceuticals Co.,Ltd proposed to distribute a cash dividend of RMB 2 (tax inclusive) per 10 Shares to all Shareholders for the year 2025. As of March 16, 2026, the Company's total share capital amounted to 6,637,199,874 Shares, of which 6,787,650 Shares were held in the stock repurchase account. Pursuant to applicable regulations, such Shares held in the stock repurchase account are not entitled to participate in the profit distribution for the current period. Based on the foregoing, the total cash dividend proposed for distribution is RMB 1,326,082,444.80 (tax inclusive). The actual amount of cash dividend to be distributed will be adjusted according to the number of Shares held in the Company's stock repurchase account as of the record date for dividend distribution.
공고 • Mar 25Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Annual General Meeting, Apr 16, 2026Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Annual General Meeting, Apr 16, 2026, at 14:30 China Standard Time. Location: No. 1288, Haike Road, Pudong New Area, Shanghai China